CSF2 and pancreatic neoplasm: GVAX is an allogeneic GM-CSF-secreting pancreatic cancer vaccine that was studied in a window-of-opportunity trial where participants were randomized to GVAX alone, GVAX with cyclophosphamide at a standard immunomodulatory dose, and GVAX with 2 week cycles of cyclophosphamide.